Sanofi (NASDAQ:SNY) Shares Sold by CIBC Asset Management Inc

CIBC Asset Management Inc lessened its stake in shares of Sanofi (NASDAQ:SNY) by 1.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 89,092 shares of the company’s stock after selling 1,325 shares during the quarter. CIBC Asset Management Inc’s holdings in Sanofi were worth $4,297,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of SNY. Synergy Asset Management LLC purchased a new stake in shares of Sanofi during the fourth quarter worth about $25,000. Concord Wealth Partners increased its position in shares of Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares during the last quarter. McClarren Financial Advisors Inc. increased its position in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the last quarter. Sunbelt Securities Inc. increased its position in shares of Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares during the last quarter. Finally, Fortitude Family Office LLC increased its position in shares of Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Stock Up 1.0 %

Shares of Sanofi stock opened at $54.13 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The firm has a market cap of $137.37 billion, a P/E ratio of 21.74, a P/E/G ratio of 1.01 and a beta of 0.57. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The business has a 50-day moving average price of $50.79 and a 200 day moving average price of $52.50.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, sell-side analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.